PCI Biotech Holding ASA (OSL:PCIB) Interest Expense: kr-0.14 Mil (TTM As of Jun. 2025)


OSL:PCIB PCI Biotech Holding ASA OSL:PCIB
6 GF Score
Price kr0.12
! 1 Warning Sign
View Full Analysis

What is PCI Biotech Holding ASA Interest Expense?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 Interest Expense is kr-0.14 Mil as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PCI Biotech Holding ASA's interest expense for the six months ended in Jun. 2025 was kr -0.08 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2025 was kr-0.14 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PCI Biotech Holding ASA's Operating Income for the six months ended in Jun. 2025 was kr -11.94 Mil. PCI Biotech Holding ASA's Interest Expense for the six months ended in Jun. 2025 was kr -0.08 Mil. PCI Biotech Holding ASA did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PCI Biotech Holding ASA  (OSL:PCIB) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PCI Biotech Holding ASA's Interest Expense for the six months ended in Jun. 2025 was kr-0.08 Mil. Its Operating Income for the six months ended in Jun. 2025 was kr-11.94 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2025 was kr0.00 Mil.

PCI Biotech Holding ASA's Interest Coverage for the quarter that ended in Jun. 2025 is calculated as

PCI Biotech Holding ASA did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

PCI Biotech Holding ASA Interest Expense Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Interest Expense Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.40 -0.09 -0.13 -0.16 -0.06

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.07 -0.04 -0.06 -0.08
OSL:PCIB
6GF Score
PCI Biotech Holding ASA OSL:PCIB
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PCI Biotech Holding ASA Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-0.14 Mil mean?
PCI Biotech Holding ASA (OSL:PCIB) has a Interest Expense of kr-0.14 Mil as of Jun. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Interest Expense too high?
PCI Biotech Holding ASA's current Interest Expense is kr-0.14 Mil. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Interest Expense compare to VRTX and REGN?
PCI Biotech Holding ASA's Interest Expense of kr-0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Interest Expense is kr-0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Interest Expense of kr-0.14 Mil. The current Interest Expense is kr-0.14 Mil. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Interest Expense is kr-0.14 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score

Get the complete analysis for OSL:PCIB

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price